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Congenital human cytomegalovirus (HCMV) infec-
tion affects 1% of children and is the most common
infectious cause of sensorineural hearing loss. Due
to the difficulty of diagnosing deafness and other
neurological disorders in infants , affected individ-
uals may not be recognized until much later when
active infection has resolved and culture is no
longer informative. To overcome this problem,
congenital HCMV infection was diagnosed retro-
spectively by testing residual blood samples col-
lected from newborns and dried on perinatal cards
as part of the North Carolina Newborn Screening
Program. We modified the Qiagen method for puri-
fying DNA from dried blood spots to increase the
sample size and recovery of the lysate. A multiplex,
real-time TaqMan polymerase chain reaction assay
on an ABI 7900 instrument measured a highly con-
served segment of the HCMV polymerase gene and
the APOB human control gene. HCMV DNA was de-
tected in blood dried on perinatal cards from all
seven infants with culture-proven congenital infec-
tion, and all 24 negative control cases lacked detect-
able HCMV DNA. Our findings suggest that it is
possible to diagnose congenital HCMV infection us-
ing dried blood collected up to 20 months earlier.
Further studies are warranted on patients with
hearing loss or other neurological deficits to deter-
mine the percentage that is attributable to congen-
ital HCMV infection. (J Mol Diagn 2006, 8:240–245; DOI:
10.2353/jmoldx.2006.050075)
Human cytomegalovirus (HCMV) infection is common in
the general population and, when primary infection oc-
curs early in pregnancy, can affect the developing neu-
rological system leading to sensorineural hearing loss
and other neurological sequelae. Congenital HCMV in-
fection is defined as HCMV infection acquired up to 3
weeks of age, either in utero or perinatally via body fluids
such as cervical mucous, breast milk, urine, or saliva.1
Congenital HCMV infection is a significant cause of fetal
and neonatal mortality and morbidity. It occurs in 1% of
all births and is symptomatic in 10 to 20% of affected
infants.2 Although symptomatic infection may also occur
on reactivation of latent maternal infection, the majority of
clinical sequelae and symptomatic infection is attribut-
able to primary maternal HCMV infection. Symptomatic
infection often involves multiple organs and is manifest as
jaundice, hepatosplenomegaly, petechial rash, micro-
cephaly, motor disability, chorioretinitis, cerebral calcifi-
cations, lethargy, respiratory distress, and seizures. Al-
most all symptomatic neonates have neurological
sequelae, most commonly sensorineural hearing loss,
and often developmental delay ranging from subtle learn-
ing disabilities to severe mental retardation. The majority
of congenitally infected infants (80 to 90%) have no clin-
ical signs or symptoms at birth, but 5 to 15% of these
asymptomatic infected infants will later be found to have
neurological sequelae, most commonly sensorineural
hearing loss.3
When a newborn is suspected of being infected by
HCMV, culture of the fetal urine or serological testing of
the mother can help determine whether HCMV infection is
the cause.2 However, when congenital infection is not
considered until later in childhood and after the active
infection has cleared, it is then difficult or impossible to
document congenital HCMV infection. Recent advances
in DNA technology have helped to overcome this barrier
to diagnosis after the newborn period. Retrospective di-
agnosis of congenital HCMV infection has been achieved
by detecting HCMV DNA in dried blood samples applied
to perinatal cards (Guthrie cards). Conventional end-
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point polymerase chain reaction (PCR) has been used to
amplify HCMV DNA from perinatal cards of children with
sensorineural hearing loss4,5 and malformations of corti-
cal development.6,7 Newborn blood is routinely collected
and dried on perinatal cards as part of state newborn
screening programs. When residual blood cards are re-
tained and made available for clinical use, it provides
new avenues for HCMV detection.
In the current study, we validated a real-time amplifi-
cation method for retrospective diagnosis of congenital
HCMV infection. DNA was extracted from dried blood on
perinatal cards and was subjected to real-time PCR am-
plification to determine the extent to which HCMV DNA
was detectable in children known to have congenital
HCMV infection. We modified the Qiagen method for
extracting DNA from dried blood spots to increase the
sample size and recovery of the lysate. Instead of using
conventional end-point PCR, we chose real-time technol-
ogy to minimize technologist time, to improve turn-around
time, and to minimize the risk of amplicon contamination,




Seven patients with culture-proven congenital HCMV in-
fection were identified by searching clinical microbiology
databases at University of North Carolina Hospitals and
Duke University Medical Center throughout the previous
2 years (Table 1). HCMV infection was detected in each
of the seven infants by urine culture at 1, 2, 4, 5, 11, 21,
or 22 days after birth. At University of North Carolina
Hospitals, urine for culture was collected and adjusted if
necessary to a slightly pink color with 5% sodium bicar-
bonate. One ml of urine was added to 1.5 ml of ice-cold
viral transport medium (Hanks’ balance salt solution with
0.5% gelatin and antibiotics), and then 0.2 ml of this
mixture (University of North Carolina Hospitals) or of un-
diluted urine (Duke University Medical Center) was inoc-
ulated into MRC-5 shell vials (human diploid fibroblasts;
Diagnostic Hybrids, Inc., Athens, OH, or Viromed Labo-
ratories, Minnetonka, MN), incubated for up to 72 hours,
and subsequently stained with anti-HCMV monoclonal
antibody (Light Diagnostics, distributed by Chemicon In-
ternational, Temecula, CA). At University of North Caro-
lina Hospitals, additional urine shell vial cultures were
examined for viral cytopathic effect twice per week for 2
weeks and once per week until at least 21 days of culture.
Alternatively, at Duke University Medical Center, conven-
tional cell culture tubes (Diagnostic Hybrids, Inc.) were
also inoculated with 0.2 ml of each patient specimen,
centrifuged at 700  g for 10 minutes, and incubated at
36°C for 14 days. Cultures were observed every other
day for characteristic cytopathic effects of HCMV. After
cytopathic effects developed, cells were scraped from
the tube and HCMV was confirmed using fluorescent
antibody targeting CMV immediate early antigens IE1
and IE2 as described above.
The perinatal cards from the seven infants with culture-
proven congenital HCMV (positive controls) and negative
control infants whose cards were filed in front of and
behind the cards from the positive control patients were
obtained from the North Carolina State Laboratory of
Public Health. Perinatal blood cards are obtained within
48 hours of birth on all infants born in North Carolina for
purposes of metabolic screening. Abnormal screening
tests are followed up by a second blood card collection.
In five of the seven positive control patients (patients A, B,
D, E, and G), another card was collected at 6 to 33 days
of age. Also, in patient F, two perinatal cards were col-
lected within 48 hours of birth (at 24 hours and 33 hours).
Because the cards from patients A and B were filed
back-to-back for the first collection, the number of nega-
tive control cards for the first collection was 12, and the
number of negative control cards for the second collec-
tion was also 12, for a total of 24 negative control cards.
Each card generally contains five blood spots, each 1 cm
in diameter. The cards were stored in the North Carolina
State Laboratory of Public Health at room temperature in
an air-conditioned environment for 2 to 20 months before
DNA extraction for this study. This investigation was con-
ducted under the supervision of our Institutional Review
Board.
In addition to the aforementioned positive and negative
control cases, we prepared mock samples from fresh
blood obtained from our clinical archives. The viral load
of each fresh blood sample had been previously mea-
sured using the same real-time PCR assay described
below except that DNA was extracted from fresh whole
blood using DNA Isolation Kit 1 on a Roche MagnaPure
instrument (Roche Molecular Systems, Indianapolis, IN).
The HCMV-negative patient blood had undetectable
Table 1. Clinical Information on Seven Patients with Culture-Proven Congenital CMV Infection
Patient ID* Age at positive urine culture (days) Clinical findings
A 21 Deceased, pneumonia, hepatitis, twin of patient B
B 22 Deceased, pneumonia, hepatitis, twin of patient A
C 2 Anemia, jaundice, respiratory distress
D 4 Not known
E 1 Not known
F 11 Not known
G 5 Not known
* Perinatal cards were obtained anonymously from the State Health Laboratory, and thus experimental laboratory results could not be linked to
clinical status. Patient B was included in the study even though the urine culture was not obtained until 1 day after the 21-day limit for defining
congenital CMV infection because the patient’s twin (patient A) was diagnosed within the limit, and both twins were symptomatic before 21 days.
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HCMV by real-time PCR to a sensitivity of 400 copies per
ml of blood and was also HCMV-seronegative (IgG and
IgM). The HCMV-positive blood was from an AIDS patient
with active HCMV infection as shown by high HCMV viral
load measurement and signs of HCMV infection by phys-
ical examination. The blood was spotted onto perinatal
cards (Schleicher and Schuell Inc., Keene, NH) in 50-l
aliquots and dried for at least 48 hours. The mock sam-
ples were used to assess the efficacy of extraction and
amplification from dried blood spots. Finally, assay sen-
sitivity and linearity was tested by spiking Towne strain
virus into HCMV-negative blood at serial 10-fold concen-
trations. The spiked blood was then spotted onto perina-
tal cards, dried, extracted, and amplified to evaluate the
performance characteristics of viral load measurement
from perinatal cards.
Perinatal Card Preparation
The newborn blood spot specimens were collected ac-
cording to NCCLS guidelines.8 Briefly, the blood samples
were taken from newborn babies’ heels and were applied
to five marked circles on newborn screening forms (made
of S&S 903 filter paper; Schleicher and Schuell Inc.),
allowed to dry, and then sent to the North Carolina State
Health Laboratory by mail or courier service. The perina-
tal cards are not covered, so each card abuts directly
against the next card in the file.
For this study, residual perinatal cards were retrieved
from the archives and shipped from the State Health
Laboratory wrapped in an individual plastic protective
cover. A pair of scissors was cleaned by making at least
20 swipes in 10% bleach, then in deionized water, and
finally in 70% ethanol. The residual ethanol was elimi-
nated by blotting on a clean tissue. An entire 1-cm-
diameter dried blood spot was cut from the perinatal card
and placed in a labeled 15-ml conical tube. A blank spot
cut from a clean piece of Schleicher and Schuell filter
paper was treated in a similar manner, as a control for
DNA contamination.
DNA Extraction
DNA was extracted from dried blood spots using the
QIAamp DNA micro kit (Qiagen, Stanford, CA). This kit is
designed to purify genomic DNA from small samples in
four steps: sample lysis, binding of lysate to the silica-gel
membrane of the QIAamp MinElute column, washing the
membrane, and eluting the DNA. We modified the man-
ufacturer’s recommended method by using the whole
dried blood spot (1 cm diameter) instead of a smaller
punch (3 mm in diameter) from the blood spot. We also
added a step in which additional lysate from the dried
blood spot was collected using a forensic spin filter that
uses centrifugal force to increase volume recovered from
solid samples.
First, the perinatal card spot was submerged in 360 l
of Buffer ATL and 40 l of proteinase K from the QIAamp
DNA micro kit (Qiagen). The conical tubes were vortexed
for 10 seconds and then incubated at 55°C for 60 min-
utes, tilting the tubes to maximize contact between the
perinatal card and the buffer, and vortexed for 10 sec-
onds approximately every 8 to 10 minutes. The perinatal
card circle was retrieved using a pipette tip and then
transferred into a forensic spin basket tube (part no.
2566; Alltech, Deerfield, IL) and spun in a microfuge at
6000  g for 5 minutes at room temperature. After this
procedure, the perinatal card circle was generally devoid
of color. If it was not completely white, the circle was
centrifuged again over the same forensic column to fur-
ther capture any remaining lysate. The recovered lysate
from this forensic filter tube was combined with the rest of
the lysate from the original conical tube, mixed with 400
l of buffer AL from the Qiagen kit, and incubated at 70°C
with intermittent vortexing according to the manufactur-
er’s instructions. The lysate was then purified over a
Qiagen spin column according to the manufacturer’s di-
rections. Note that loading of the lysate onto the column
required two spins of 400 l each due to the doubled
volume of lysate (800 l). The column was washed ac-
cording to the manufacturer’s instructions. DNA was
eluted into 100 l of AE buffer, and 10 l was used in
each amplification reaction except as noted.
Amplification
The purified DNA was tested in a multiplex, real-time PCR
assay to detect a highly conserved segment of the HCMV
polymerase (POL) gene and a control human gene
(APOB) using primers and TaqMan probes described by
Sanchez and Storch,9 except we labeled the 5 end of the
APOB probe with TET (tetrachlorofluorescein) and the 3
ends of both HCMV and APOB probes with the quencher
dye TAMRA (carboxytetramethylrhodamine). The 5 end
of the HCMV probe was labeled with FAM (6-carboxy-
fluorescein). Primers and labeled TaqMan probes were
purchased from TIB Molbiol LLC, Adelphia, NJ. Purified
HCMV DNA was prepared by culturing early-passage
Towne strain HCMV and purifying extracellular viral par-
ticles on a CsCl gradient. After extraction, the purified
HCMV DNA was quantified against serial dilutions of a
commercially available HCMV DNA standard (CMV
AD169 quantitated viral DNA; Advanced Biotechnolo-
gies, Inc.). Five serial 10-fold dilutions of the Towne strain
DNA from 80,000 to 8 copies of HCMV per PCR served as
the standard for Q-PCR measurement of HCMV.
PCR was performed in a 50-l volume containing Taq-
Man 2 Universal PCR Master Mix (Applied Biosystems,
Foster City, CA), 250 nmol each of the four primers, and
37.5 nmol each of the two labeled probes, 10 l of
template DNA, and nuclease-free water. Reactions were
performed on a Prism 7900 sequence detection system
(ABI) using universal cycling parameters as follows: after
an initial hold at 50°C for 2 minutes, denaturation was at
95°C for 10 minutes followed by 45 cycles of denaturation
at 95°C for 15 seconds and extension at 60°C for 1
minute. To check for amplicon contamination, multiple
samples containing no template were included in every
run.
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Results
The accuracy of the perinatal card extraction and ampli-
fication method for detecting HCMV DNA was evaluated
by creating mock samples. Two blood samples drawn on
2 different days from an AIDS patient known to have
active HCMV infection were chosen because of their high
HCMV viral load (298,687 and 392,094 copies/ml of fresh
blood). A third blood sample having no detectable HCMV
DNA to a sensitivity of 400 copies per ml of fresh whole
blood was used as a negative control. A known volume
(50 l) of fresh whole blood from each of the three pa-
tients was applied to filter paper in triplicate and then
dried for at least 48 hours. DNA was extracted from the
blood spots and PCR amplified. The percentage recov-
ery of HCMV DNA from the filter paper based on the
known copy number applied to the filter paper was 81%
for both samples from the AIDS patient, whereas the
negative control had no detectable HCMV DNA (data not
shown). Control APOB DNA was amplified in all mock
samples.
Assay Linearity and Sensitivity
Assay linearity on dried blood from perinatal cards was
evaluated by preparing serial dilutions of HCMV DNA
(Towne strain) into HCMV-negative whole blood at con-
centrations of 80,000 copies/5 l blood (C1), 8000 cop-
ies/5 l blood (C2), 800 copies/5 l blood (C3), 80 cop-
ies/5 l blood (C4), and 8 copies/5 l blood (C5). A
known volume (50 l) of each dilution was applied to filter
paper in triplicate spots. The DNA from each spot was
extracted from the filter paper and 10 l of the 100-l
elute was used in each PCR assay, equivalent to testing
5 l of whole blood. Reproducibility was assessed by
extracting and amplifying duplicates on 1 day and the
triplicate spot on a different day. The correlation coeffi-
cient (R2 value) for each of the three serial dilutions was
0.997, 0.989, and 0.996 (Figure 1). The mean threshold
cycle (Ct) and SD of the reproducibility data for the
Towne strain virus serial dilutions at each serial dilution
was 27.4  0.7 (C1), 31.5  0.5 (C2), 35.3  0.2 (C3),
39.6  0.9 (C4), and 44.8  0.1 (C5). The sensitivity of
the PCR assay is eight copies of HCMV DNA per PCR
reaction, based on the highest dilution of purified HCMV
DNA that consistently yielded measurable results. This
translates to a sensitivity of 1600 copies/ml of whole
blood, or 80 copies of HCMV DNA in a 1.0  1.0-cm dried
blood spot containing 50 l of whole blood. In conclu-
sion, the extraction and amplification of HCMV DNA from
perinatal cards is sensitive and linear over five-log con-
centrations of viral load.
Clinical Validation in Perinatal Card Samples
The perinatal cards of seven patients with culture-proven
congenital HCMV infection were used as positive con-
trols, whereas control infants whose cards were filed in
front of and behind the cards from the positive control
patients served as negative controls. A card on which no
blood was spotted served as a control for amplicon con-
tamination, and it showed no amplifiable HCMV or APOB
DNA. HCMV DNA was detected in all seven positive
control patient blood spots collected at less than 48
hours of age (Table 2) but was not detected in any
negative control perinatal cards. The human APOB gene
was amplified in all 24 negative controls (including 12
negative controls associated with the earliest collection
time point of 48 hours, see APOB values in Table 2).
The HCMV PCR assay, as applied to blood spots on
perinatal cards, is not quantitative because the volume of
blood in each spot is undoubtedly variable. Furthermore,
APOB level is not an ideal normalizer because the white
cell count of each infant may vary, and the efficiency of
extraction from each blood spot may vary. Nevertheless,
if we assume that the blood spots contained similar vol-
umes of blood and extraction was similarly efficient
across all cases, then it is clear that the HCMV viral load
varied considerably among the seven infants with con-
genital HCMV infection (Table 2). Higher cycle thresholds
(suggesting lower viral loads) were evident in patients 3,
5, and 7. The lowest level was evident in patient 7 in
whom the cycle threshold was reached very close to the
end of the amplification cycles. The highest viral levels
were seen in patients 1, 4, and 6. Remarkably, even the
negative control card(s) directly abutting these patient’s
highly viremic cards contained no detectable HCMV
DNA.
Figure 1. Real-time PCR of CMV DNA extracted and amplified from Guthrie cards reveals that the assay is sensitive and linear. A: Amplification plot shows change
in fluorescence on the y axis (Rn) and PCR cycle number on the x axis. Standards contain varying levels of CMV DNA as follows: C1, 80,000 copies/5 l blood;
C2, 8000 copies/5 l blood; C3, 800 copies/5 l blood; C4, 80 copies/5 l blood; C5, 8 copies/5 l blood. B: Standard curve shows cycle threshold (Ct) on the
y axis and template DNA level on the x axis. Correlation coefficient (R2)  0.989. Linearity drops off with the highest dilution (C5).
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Using 10 l of starting template DNA was sufficient to
detect all positive control patients. To determine whether
even more starting template DNA was better for detecting
samples with low viral load, all PCR assays were re-
peated using 20 l of starting template. Although all
seven positive control patients still had measurable
HCMV DNA, control DNA amplification of the human
APOB gene was not as robust, possibly because of PCR
inhibitors associated with too much template DNA. To
maximize the HCMV detection rate, it is recommended
that the PCR assay be run in duplicate using 10 l of
template in each well.
In some infants, multiple blood cards were available for
testing. In general, the viral loads were lower for the cards
collected at less than 48 hours than at later time points in
the same infant, with the caveat that there was no control
for the amount of blood on each card or the efficiency of
DNA recovered from each card (data not shown). All of
the negative control cards filed in front of and behind
these patient cards had undetectable HCMV DNA and
amplifiable APOB DNA, with minimal APOB variation
(data not shown).
Discussion
This is the first study to show that real-time amplification
of HCMV DNA in perinatal cards is reliable for detecting
congenital HCMV infection in neonates. Several groups
of investigators have used conventional PCR to amplify
HCMV DNA extracted from blood spots on perinatal
cards.4–7,10–14 The most recent studies7,14 used the
method of Barbi and colleagues,4 which involves heat
extraction followed by a nested PCR reaction amplifying
the HCMV glycoprotein B (gB) gene and detection by
agarose gel electrophoresis. This method was 100% sen-
sitive and 99% specific compared with viral culture in 509
babies with congenital HCMV infection defined by
culture.
In this study, HCMV DNA was detected in all seven
cases of culture-proven congenital HCMV infection,
whereas all negative control cases lacked detectable
HCMV DNA. The number of patients tested was limited
by the length of time the perinatal cards were stored in
North Carolina (2 years after birth). The efficacy of DNA
extraction and amplification in each sample was proven
by successful amplification of a human APOB gene seg-
ment. We modified the manufacturer’s recommended ex-
traction method by using the whole dried blood spot (1
cm in diameter) instead of a smaller punch (3 mm in
diameter) from the blood spot. The yield of sample lysate
was increased by using a forensic spin basket filter to
capture additional volume from the perinatal card. A ma-
jor advantage of real-time PCR over the nested PCR
method used by other investigators is the minimal risk of
amplicon contamination and the less labor intensive, and
therefore less costly, protocol. It should be noted that the
sensitivity in our assay (1600 copies/ml) is not as low as
that described in the nested PCR method (400 copies/
ml).15 Nevertheless, a real-time PCR method has analyt-
ical and clinical benefits, and it may be applicable to
other laboratory assays targeting low-level DNA in blood
card samples.
Although the assay is semiquantitative, it is probably
not clinically relevant to report results of perinatal card
testing in a quantitative manner. We suggest that viral
PCR results be reported qualitatively as either “HCMV
DNA was present in DNA extracted from the perinatal
dried blood spot, consistent with a diagnosis of congen-
ital HCMV infection” or “HCMV DNA was not detected in
DNA extracted from the perinatal dried blood spot, sug-
gesting no active HCMV infection at the time of neonatal
blood collection.” In the latter case, a diagnosis of con-
genital HCMV infection is not ruled out because infection
occurring early in gestation may have resolved by the
perinatal period. Also, a congenital infection (defined as
acquired in utero or up to 3 weeks after birth) may be
acquired after birth (for example, from exposure in the
newborn nursery).
The frequency at which asymptomatic newborns have
occult HCMV infection deserves study. Further studies
Table 2. Replicate Real-Time Amplification of the HCMV Polymerase Gene and the Human APOB Gene in Perinatal Cards
Obtained at Less than 48 Hours of Age
Patient number* HCMV POL cycle threshold† APOB control cycle threshold†
Positive controls
1 33, 34 34, 34
2 40, 40 32, 31
3 42, 43 36, 36
4 38, 37 31, 32
5 42, 38 32, 32
6 36, 36 36, 36
7 45, 43 31, 32
1 to 7 Mean: 39  4 Mean: 33  2
Median: 39 Median: 32
Range: 33 to 45 Range: 31 to 36
Negative controls
8 to 19 Undetectable Mean: 32  2
Median: 31
Range: 31 to 36
*Patient number is random; perinatal cards were obtained anonymously from the State Health Laboratory and thus experimental laboratory results
could not be correlated with clinical status.
†Replicates are shown for positive control patients.
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are also warranted on perinatal cards of patients with
sensorineural hearing loss or other neurological deficits
to determine the percentage attributable to congenital
HCMV infection. Barbi and colleagues5 used the nested
PCR method to test Guthrie cards in children with senso-
rineural hearing loss, and 20 to 30% of cases were at-
tributable to congenital HCMV infection. Congenital
HCMV infection also causes other neurological sequelae
such as microcephaly, seizures, mental retardation, pa-
resis, and paralysis. Zucca and colleagues7 recently ret-
rospectively diagnosed congenital HCMV infection in 4 of
10 patients with malformations of cortical development by
detecting HCMV DNA in dried blood spots. Our new
assay provides a useful tool for similar retrospective clin-
ical studies.
Testing perinatal cards is not recommended for diagno-
sis of active, symptomatic HCMV infection in a neonate.
Instead, viral culture or PCR of fresh blood or body fluids/
tissues are the diagnostic methods of choice. Perinatal card
testing is indicated when congenital HCMV infection is in
the differential diagnosis of a patient who has an appropri-
ate clinical finding (eg, hearing loss or other neurological
sequelae) that is recognized later in childhood when the
active infection has resolved and current testing is no longer
informative. We recommend testing all of the available
blood cards that were collected during the first 3 weeks
after birth, because it is possible that viral load increases
throughout time as maternal antibodies wane in the infant.
Although retrospective diagnosis of congenital HCMV infec-
tion is too late to influence antiviral treatment decisions,
diagnosis of an infectious cause of a neurological disorder
is reassuring to parents in that a genetic cause (although
not completely excluded) is less likely. Therefore, subse-
quent pregnancies of the parents and patients are not ex-
pected to be affected. However, because infectious and
genetic causes of hearing loss (such as connexin gene
mutations or a genetic syndrome) could potentially co-exist,
genetic causes of hearing loss or other neurological se-
quelae should still be pursued if clinically indicated. Finally,
retrospective studies will provide valuable epidemiological
information to further define the spectrum of neurological
deficits attributable to HCMV infection and the percentage
attributable to HCMV infection. Although perinatal card test-
ing is considered a retrospective diagnostic test, Binda and
colleagues15 have recently proposed dried blood spot test-
ing for congenital HCMV infection for the purpose of new-
born screening. This application may allow timely diagnosis
and treatment, even in the absence of concurrent signs or
symptoms, and may improve long-term outcome.
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